{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:38:57Z","timestamp":1775381937728,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1053\/j.seminoncol.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T22:36:31Z","timestamp":1642631791000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Modern radiographic imaging in multiple myeloma, what is the minimum requirement?"],"prefix":"10.1053","volume":"49","author":[{"given":"Esther","family":"Mena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evrim B.","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Lindenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.007_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.007_bib0002","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0003","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.007_bib0004","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1148\/rg.2019180096","article-title":"Whole-body imaging of multiple myeloma: diagnostic criteria","volume":"39","author":"Ormond Filho","year":"2019","journal-title":"Radiographics"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"Grebbell FS. The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin Radiol"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.007_bib0006","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ejrad.2013.08.036","article-title":"Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM)","volume":"82","author":"Ippolito","year":"2013","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0007","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejrad.2004.04.015","article-title":"Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography","volume":"54","author":"Horger","year":"2005","journal-title":"Eur J Radiol"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.007_bib0008","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ejrad.2014.02.008","article-title":"Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease","volume":"83","author":"Wolf","year":"2014","journal-title":"Eur J Radiol"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0009","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2016.146092","article-title":"Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.007_bib0010","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/07357907.2013.764565","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill","year":"2013","journal-title":"Cancer Invest"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.007_bib0011","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0012","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.007_bib0013","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0014","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","article-title":"Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group","volume":"8","author":"Moulopoulos","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0016","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminoncol.2022.01.007_bib0017","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0018","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.007_bib0021","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \"early myeloma\"","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1053\/j.seminoncol.2022.01.007_bib0022","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.007_bib0023","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2022.01.007_bib0024","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0025","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.007_bib0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0028","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","article-title":"Low hexokinase-2 expression-associated false-negative (18)F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J Surg Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.007_bib0030","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0031","first-page":"1592","article-title":"Vellenga E. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment","volume":"47","author":"Agool","year":"2006","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0032","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.007_bib0033","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.18632\/oncotarget.3053","article-title":"11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma","volume":"6","author":"Luckerath","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.007_bib0034","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15252\/emmm.201404698","article-title":"In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma","volume":"7","author":"Philipp-Abbrederis","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0035","first-page":"200","article-title":"Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival","volume":"91","author":"Vande Broek","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.007_bib0036","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-019-04605-z","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"47","author":"Pan","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0037","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0038","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0039","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.007_bib0040","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of multiple myeloma: from xenograft models to first-in-human imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"20","key":"10.1053\/j.seminoncol.2022.01.007_bib0041","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","article-title":"Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab","volume":"4","author":"Krishnan","year":"2020","journal-title":"Blood Adv"},{"issue":"43","key":"10.1053\/j.seminoncol.2022.01.007_bib0042","doi-asserted-by":"crossref","first-page":"20485","DOI":"10.1039\/C9NR06512A","article-title":"Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma","volume":"11","author":"Detappe","year":"2019","journal-title":"Nanoscale"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0043","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1148\/radiol.2522081756","article-title":"Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging","volume":"252","author":"B\u00e4uerle","year":"2009","journal-title":"Radiology"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0044","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejrad.2005.01.017","article-title":"Role of MRI for the diagnosis and prognosis of multiple myeloma","volume":"55","author":"Baur-Melnyk","year":"2005","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.007_bib0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.007_bib0046","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1007\/s00330-015-4195-0","article-title":"Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology","volume":"26","author":"Mai","year":"2016","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.007_bib0047","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ajh.23258","article-title":"Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients","volume":"87","author":"Moulopoulos","year":"2012","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.007_bib0048","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0049","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.02.012","article-title":"Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or (18)F-fluorodeoxyglucose positron emission tomography\/CT ((18)F-FDG PET\/CT) in patients with myeloma: Systematic review of diagnostic performance","volume":"124","author":"Gariani","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.007_bib0050","first-page":"1687","article-title":"Whole-body MRI of bone marrow: a review","volume":"50","author":"Hynes","year":"2019","journal-title":"J MRI"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0051","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0052","article-title":"Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma","author":"Zhang","year":"2020","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.007_bib0053","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1148\/radiol.2016160363","article-title":"Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma","volume":"282","author":"Koutoulidis","year":"2016","journal-title":"Radiology"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0054","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2214\/AJR.11.8185","article-title":"Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI","volume":"200","author":"Padhani","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108695","article-title":"Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study","volume":"120","author":"Zhang","year":"2019","journal-title":"European Journal of Radiology"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.007_bib0056","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40644-020-0293-6","article-title":"Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response","volume":"20","author":"Park","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.seminoncol.2022.01.007_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2020.109403","article-title":"The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT","volume":"133","author":"Paternain","year":"2020","journal-title":"Eur J Radiol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:58:18Z","timestamp":1758805098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0093775422000070"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.007","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern radiographic imaging in multiple myeloma, what is the minimum requirement?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}